Evidence map›Paper›PMID 37439010›Full record

ArticleDrug delivery2023

Construction and application of microneedle-mediated photothermal therapy and immunotherapy combined anti-tumor drug delivery system.

Jiaqi Weng, Gensuo Zheng, Jiaoli Wen, Jing Yang, Qingliang Yang, Xi Zheng, Qinying Yan

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jiaqi WengCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China.ORCID 0000-0002-2756-2682
Gensuo ZhengCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China.
Jiaoli WenCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China.
Jing YangCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China.
Qingliang YangCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China.
Xi ZhengAnalysis Center of Agrobiology and Environmental Sciences, Zhejiang University, Hangzhou, P.R. China.
Qinying YanCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P.R. China.
Zhejiang University of Technology · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional treatments for tumors were frequently accompanied by drawbacks and side effects. It might be useful to use the revolutionary microneedle technology which combines photothermal therapy with tumor immunotherapy. In this study, we created a microneedle drug delivery system with mercapto-modified gold nanorods and immune checkpoint blocker anti-PD-1 polypeptide. With good mechanical strength, the microneedle system can efficiently penetrate the skin and deliver drugs. When inserted into human skin, anti-PD-1 peptides and gold nanorods can be released, boosting the capacity of cytotoxic T lymphocytes to destroy tumor cells. Additionally, the elimination of the tumor is aided by the production of heat while being exposed to near-infrared light. This microneedle drug delivery system can enhance the immunological reaction and prolong the survival time of mice. Moreover, it has been demonstrated that the system has mild toxic and side effects on normal tissues and can effectively inhibit the growth of tumors, indicating a bright prospect for the treatment of cancers.

Indexed as

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsAnimalsDrug Delivery SystemsGoldHumansImmunotherapyMicePhotothermal TherapyAntineoplastic AgentsGoldCancer immunotherapydissolving microneedlesphotothermal therapytranscutaneous immunization

Identifiers

PMID37439010
PMCPMC10348037
OpenAlexW4384120821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.